These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 1977497)

  • 21. Neurotransmitter receptor alterations in Huntington's disease: autoradiographic and homogenate studies with special reference to benzodiazepine receptor complexes.
    Whitehouse PJ; Trifiletti RR; Jones BE; Folstein S; Price DL; Snyder SH; Kuhar MJ
    Ann Neurol; 1985 Aug; 18(2):202-10. PubMed ID: 2994554
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Morphologic and histochemical characteristics of a spared subset of striatal neurons in Huntington's disease.
    Ferrante RJ; Kowall NW; Beal MF; Martin JB; Bird ED; Richardson EP
    J Neuropathol Exp Neurol; 1987 Jan; 46(1):12-27. PubMed ID: 2947977
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Somatostatin and neuropeptide Y concentrations in pathologically graded cases of Huntington's disease.
    Beal MF; Mazurek MF; Ellison DW; Swartz KJ; McGarvey U; Bird ED; Martin JB
    Ann Neurol; 1988 Jun; 23(6):562-9. PubMed ID: 2900622
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Abnormal scaffold attachment factor 1 expression and localization in spinocerebellar ataxias and Huntington's chorea.
    Buckner N; Kemp KC; Scott HL; Shi G; Rivers C; Gialeli A; Wong LF; Cordero-LLana O; Allen N; Wilkins A; Uney JB
    Brain Pathol; 2020 Nov; 30(6):1041-1055. PubMed ID: 32580238
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neurochemical substrates of rigidity and chorea in Huntington's disease.
    Storey E; Beal MF
    Brain; 1993 Oct; 116 ( Pt 5)():1201-22. PubMed ID: 7693298
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Striatal D1 and D2 receptor binding in patients with Huntington's disease and other choreas. A PET study.
    Turjanski N; Weeks R; Dolan R; Harding AE; Brooks DJ
    Brain; 1995 Jun; 118 ( Pt 3)():689-96. PubMed ID: 7600086
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An immunohistochemical investigation of the human neostriatum in Huntington's disease.
    Goto S; Hirano A; Rojas-Corona RR
    Ann Neurol; 1989 Mar; 25(3):298-304. PubMed ID: 2543263
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Survival of basal ganglia neuropeptide Y-somatostatin neurones in Huntington's disease.
    Dawbarn D; De Quidt ME; Emson PC
    Brain Res; 1985 Aug; 340(2):251-60. PubMed ID: 2862959
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Huntington's chorea. Changes in neurotransmitter receptors in the brain.
    Enna SJ; Bird ED; Bennett JP; Bylund DB; Yamamura HI; Iversen LL; Snyder SH
    N Engl J Med; 1976 Jun; 294(24):1305-9. PubMed ID: 4733
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Chorea.
    Klawans HL
    Can J Neurol Sci; 1987 Aug; 14(3 Suppl):536-40. PubMed ID: 2445458
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Striatal dopamine and homovanillic acid in Huntington's disease.
    Reynolds GP; Garrett NJ
    J Neural Transm; 1986; 65(2):151-5. PubMed ID: 2939198
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Vesicular neurotransmitter transporters in Huntington's disease: initial observations and comparison with traditional synaptic markers.
    Suzuki M; Desmond TJ; Albin RL; Frey KA
    Synapse; 2001 Sep; 41(4):329-36. PubMed ID: 11494403
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sparing of striatal neurons coexpressing calretinin and substance P (NK1) receptor in Huntington's disease.
    Cicchetti F; Gould PV; Parent A
    Brain Res; 1996 Aug; 730(1-2):232-7. PubMed ID: 8883909
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Somatostatin is increased in the nucleus accumbens in Huntington's disease.
    Beal MF; Bird ED; Langlais PJ; Martin JB
    Neurology; 1984 May; 34(5):663-6. PubMed ID: 6143284
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Corticotropin-releasing hormone (CRH) is decreased in the basal ganglia in Huntington's disease.
    De Souza EB; Whitehouse PJ; Folstein SE; Price DL; Vale WW
    Brain Res; 1987 Dec; 437(2):355-9. PubMed ID: 2893655
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Huntington's chorea: selective depletion of activity of angiotensin coverting enzyme in the corpus striatum.
    Arregui A; Bennett JP; Bird ED; Yamamura HI; Iversen LL; Snyder SH
    Ann Neurol; 1977 Oct; 2(4):294-8. PubMed ID: 214022
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Huntington's disease progression. PET and clinical observations.
    Andrews TC; Weeks RA; Turjanski N; Gunn RN; Watkins LH; Sahakian B; Hodges JR; Rosser AE; Wood NW; Brooks DJ
    Brain; 1999 Dec; 122 ( Pt 12)():2353-63. PubMed ID: 10581228
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neurochemical alterations in Huntington's chorea: a study of post-mortem brain tissue.
    Spokes EG
    Brain; 1980 Mar; 103(1):179-210. PubMed ID: 6102490
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Striatal glucose metabolism and dopamine D2 receptor binding in asymptomatic gene carriers and patients with Huntington's disease.
    Antonini A; Leenders KL; Spiegel R; Meier D; Vontobel P; Weigell-Weber M; Sanchez-Pernaute R; de Yébenez JG; Boesiger P; Weindl A; Maguire RP
    Brain; 1996 Dec; 119 ( Pt 6)():2085-95. PubMed ID: 9010012
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pallidal GABA and chorea in Huntington's disease.
    Pearson SJ; Heathfield KW; Reynolds GP
    J Neural Transm Gen Sect; 1990; 81(3):241-6. PubMed ID: 2144428
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.